Early evolocumab improves lipid profile, inflammation and short-term outcomes in non-revascularized CHIP-NSTEACS patients: a retrospective cohort study
Objective To evaluate the lipid-lowering efficacy, anti-inflammatory activity, and short-term prognostic benefit of early evolocumab plus statin in complex high-risk indicated non-revascularized non-ST-elevation acute coronary syndrome (CHIP-NSTEACS) patients. Methods This single-center retrospective cohort study conse...